https://youtu.be/gtE3SROFPXg

New resource available view now
Related Posts

POTOMAC, Maryland – October 13, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company advancing Alzheimer’s disease therapeutics and Artificial Intelligence (AI)-enabled healthcare technologies, today

How Sleep Supports Brain Health
Contrary to common belief, sleep is a very active process that keeps our body (and especially our brain) in tip-top shape. It turns out that taking good care of your

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026
POTOMAC, Maryland – September 28, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead

POTOMAC, Maryland – August 28, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics and AI-enabled tools for Alzheimer’s disease, today announced

Alzheimer’s Across Borders: A Global look at regional patterns and drivers of Alzheimer’s Disease
Regional differences in Alzheimer’s Disease prevalence are often linked with factors such as health infrastructure, socioeconomic status, and lifestyle choices. Addressing these disparities requires a deeper understanding of how culture,